Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Antiepileptic — SV2A Ligand (Focal Seizures)

Brivaracetam

Brand names: Briviact

Brivaracetam is an antiseizure medication used as monotherapy or adjunctive therapy for focal (partial-onset) seizures with or without secondary generalisation in epilepsy.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds with high affinity and selectivity to synaptic vesicle protein 2A (SV2A) in the brain, modulating neurotransmitter release to reduce neuronal hyperexcitability.

Prescribing in practice

  • Withdraw gradually rather than abruptly to reduce the risk of rebound seizures or status epilepticus.
  • It is a structural analogue of levetiracetam and shares a similar profile; dose adjustment is needed in hepatic impairment.
  • Available in oral and intravenous formulations, allowing transition when oral administration is temporarily not feasible.

Monitoring

Monitor seizure frequency and for psychiatric and behavioural adverse effects such as irritability, depression or aggression, particularly early in treatment.

Counselling the patient

  • Do not stop the medicine suddenly; any change should be made under specialist guidance.
  • Report any mood changes, agitation or suicidal thoughts promptly.
  • Tell the team about all other medicines, as concurrent enzyme-inducing drugs may affect levels.

Evidence & guidelines

Brivaracetam is recommended within NICE guidance as an option for focal seizures, supported by placebo-controlled adjunctive trials.

Reference: NICE TA564 (Brivaracetam as Adjunctive Therapy); EMA SmPC Briviact; BRIVARACETAM Phase III Trials; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways